Ignite Creation Date:
2024-05-06 @ 8:32 AM
Last Modification Date:
2024-10-26 @ 12:01 PM
Study NCT ID:
NCT02761694
Status:
TERMINATED
Last Update Posted:
2023-05-06
First Post:
2016-04-29
Brief Title:
Vevorisertib ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents in Solid Tumors With PIK3CA AKT PTEN Mutations MK-4440-001
Sponsor:
ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA
Organization:
ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA
Organization Data
Organization:
ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA
Class:
INDUSTRY
Study ID:
4440-001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
ArQule Inc a subsidiary of Merck Sharp Dohme LLC a subsidiary of Merck Co Inc Rahway NJ USA
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None